TG Therapeutics Plans Cut-Price Challenger To Ocrevus In MS
Filing Expected In Q3
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.
You may also be interested in...
Janssen is the latest big pharma company to gain an approval for a new oral multiple sclerosis therapy in the EU, enhancing the competitiveness of the marketplace, and giving more choice for patients.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
An attempt to show efficacy even in younger people with mild COVID-19 symptoms has fallen flat in Phase II, and AT-527 will now lag behind rivals Merck and Pfizer.